CS
AMRX icon

Credit Suisse’s Amneal Pharmaceuticals AMRX Stock Holding History

Credit Suisse’s Portfolio AMRX Stock Details AMRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		$943K Hold
155,646
– – ﹤0.01% 2305
2023
Q4 		$945K Buy
+155,646
New +$693K ﹤0.01% 2363
2023
Q2 		– Sell
-61,879
Closed -$86K – 3167
2023
Q1 		$86K Buy
61,879
+25
+0% +$50 ﹤0.01% 3216
2022
Q4 		$123K Sell
61,854
-245
-0.4% -$549 ﹤0.01% 3294
2022
Q3 		$124K Buy
62,099
+591
+1% +$1.66K ﹤0.01% 3392
2022
Q2 		$196K Buy
61,508
+555
+0.9% +$2.01K ﹤0.01% 3339
2022
Q1 		$255K Buy
60,953
+4,722
+8% +$20.9K ﹤0.01% 3287
2021
Q4 		$270K Sell
56,231
-2,313
-4% -$11.5K ﹤0.01% 4164
2021
Q3 		$313K Buy
58,544
+4,282
+8% +$21.6K ﹤0.01% 4071
2021
Q2 		$280K Sell
54,262
-9,679
-15% -$55K ﹤0.01% 4140
2021
Q1 		$430K Sell
63,941
-45,325
-41% -$251K ﹤0.01% 3860
2020
Q4 		$499K Buy
109,266
+43,993
+67% +$195K ﹤0.01% 3804
2020
Q3 		$253K Sell
65,273
-17,300
-21% -$74K ﹤0.01% 3739
2020
Q2 		$393K Sell
82,573
-186,032
-69% -$766K ﹤0.01% 3453
2020
Q1 		$935K Buy
268,605
+177,180
+194% +$750K ﹤0.01% 2700
2019
Q4 		$441K Buy
91,425
+31,675
+53% +$110K ﹤0.01% 3639
2019
Q3 		$174K Sell
59,750
-38,328
-39% -$134K ﹤0.01% 3891
2019
Q2 		$703K Sell
98,078
-34,382
-26% -$352K ﹤0.01% 3184
2019
Q1 		$1.88M Buy
132,460
+70,144
+113% +$927K ﹤0.01% 2418
2018
Q4 		$844K Buy
62,316
+9,089
+17% +$164K ﹤0.01% 2913
2018
Q3 		$1.18M Sell
53,227
-491,023
-90% -$10.3M ﹤0.01% 2739
2018
Q2 		$8.93M Buy
+544,250
New +$9.55M 0.01% 1300

Other funds holding AMRX

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
TGA
TPG GP A Fort Worth, Texas $3.68B AUM 14.99% 1-Year Est. Return
FI
Fosun International Hong Kong, China $399M AUM 16.11% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Neuberger Berman Group
Neuberger Berman Group New York $131B AUM 28.36% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Credit Suisse's AMRX Position: Q1 2024 in Review

Credit Suisse held its Amneal Pharmaceuticals (AMRX) position steady in Q1 2024 at 155,646 shares worth $943K. The position accounts for ﹤0.01% of the portfolio, ranked #2305.

Credit Suisse first reported a position in AMRX in Q2 2018 and has held it in 22 quarters since. The position peaked at $8.93M in Q2 2018. 176 funds tracked by Wall St. Rank hold AMRX as of Q1 2024.

  • Credit Suisse held 155,646 shares of Amneal Pharmaceuticals worth $943K as of Q1 2024.
  • Credit Suisse left its Amneal Pharmaceuticals share count unchanged in Q1 2024.
  • Amneal Pharmaceuticals made up ﹤0.01% of Credit Suisse's portfolio in Q1 2024, its #2305 holding.
  • Credit Suisse first reported a position in Amneal Pharmaceuticals in Q2 2018 and has held it in 22 quarters since.
  • Credit Suisse's Amneal Pharmaceuticals position peaked at $8.93M in Q2 2018.
  • 176 funds tracked by Wall St. Rank held Amneal Pharmaceuticals as of Q1 2024.

Based on Credit Suisse's 13F filing for Q1 2024, filed 10 May 2024.